Gilder Gagnon Howe & Co. LLC Has $32.07 Million Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Gilder Gagnon Howe & Co. LLC raised its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 2.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 281,412 shares of the company's stock after acquiring an additional 5,581 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned approximately 0.12% of BioNTech worth $32,067,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp raised its position in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after acquiring an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its position in shares of BioNTech by 823.5% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after buying an additional 700 shares during the last quarter. Allianz SE acquired a new position in shares of BioNTech in the 4th quarter valued at $90,000. GAMMA Investing LLC grew its position in shares of BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock valued at $105,000 after buying an additional 300 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new stake in BioNTech during the 4th quarter worth $137,000. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Price Performance

Shares of NASDAQ BNTX remained flat at $104.00 during trading on Tuesday. 1,222,075 shares of the stock were exchanged, compared to its average volume of 908,112. The business's fifty day moving average price is $101.41 and its 200-day moving average price is $110.43. The company has a market cap of $24.96 billion, a P/E ratio of -49.52 and a beta of 1.07. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. During the same quarter in the previous year, the firm posted $1.90 earnings per share. The company's revenue was down 19.5% compared to the same quarter last year. As a group, sell-side analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have issued reports on BNTX shares. Morgan Stanley decreased their price objective on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. Truist Financial assumed coverage on BioNTech in a research report on Friday, January 10th. They issued a "buy" rating and a $172.00 target price for the company. HC Wainwright cut their price target on BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Citigroup started coverage on BioNTech in a report on Thursday, March 13th. They issued a "buy" rating and a $145.00 price objective for the company. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 target price on shares of BioNTech in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and a consensus price target of $143.44.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.